Page last updated: 2024-11-08

qlt 0267

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID228619
CHEMBL ID1765295
CHEMBL ID1389127
CHEMBL ID4296845
SCHEMBL ID924770
SCHEMBL ID3837104
MeSH IDM0550219

Synonyms (55)

Synonym
HMS1678I10
CBMICRO_025229
nsc-21678
6975-75-3
nsc21678
mls000737992 ,
BIM-0025196.P001
smr000283426
4-[(e)-(4-methoxyphenyl)diazenyl]-1h-pyrazole-3,5-diamine
STK020105
AKOS000489389
AKOS000505985
AKOS001707734
(4e)-5-imino-4-[2-(4-methoxyphenyl)hydrazinylidene]-4,5-dihydro-1h-pyrazol-3-amine
STK673961
CHEMBL1765295
AKOS005220713
CCG-12601
[(3-amino-5-imino(1,2-diazolin-4-ylidene))azamethyl](4-methoxyphenyl)amine
HMS2768H08
F1443-7492
(e)-4-((4-methoxyphenyl)diazenyl)-1h-pyrazole-3,5-diamine
99285-51-5
4-[(4-methoxyphenyl)hydrazono]-4h-pyrazole-3,5-diamine
866409-68-9
SCHEMBL924770
SCHEMBL3837104
DTXSID60415318
CHEMBL1389127
(4e)-5-imino-4-[2-(4-methoxyphenyl)hydrazin-1-ylidene]-4,5-dihydro-1h-pyrazol-3-amine
4-[(4-methoxyphenyl)diazenyl]-1h-pyrazole-3,5-diamine
3,5-diamino-4-(4-methoxyphenylazo)-1h-pyrazole
qlt-0267
E75363
3-amino-4-[(e)-2-(4-methoxyphenyl)diazenyl]-1h-pyrazol-5-ylamine
HY-115677
ilk-in-3
BRD-K81404764-001-08-0
4-[2-(4-methoxyphenyl)hydrazinylidene]pyrazolidine-3,5-diimine
STL437867
qlt0267
CS-0104348
qlt-0267; qlt 0267; qlt0267; qlt-267; qlt 267; qlt267
BCP25954
CHEMBL4296845
BS-47854
DTXSID00903507
noname_4187
4-((4-methoxyphenyl)diazenyl)-1h-pyrazole-3,5-diamine
4-(2-(4-methoxyphenyl)hydrazineylidene)-4h-pyrazole-3,5-diamine
nsc-812441
nsc812441
4-(4-methoxy-phenylazo)-1h-pyrazole-3,5-diamine
4-[(1e)-2-(4-methoxyphenyl)diazen-1-yl]-1h-pyrazole-3,5-diamine
AKOS040759441
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (15)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, JmjC domain-containing histone demethylation protein 3AHomo sapiens (human)Potency44.66840.631035.7641100.0000AID504339
LuciferasePhotinus pyralis (common eastern firefly)Potency19.01150.007215.758889.3584AID588342
BRCA1Homo sapiens (human)Potency10.00000.89137.722525.1189AID624202
ATAD5 protein, partialHomo sapiens (human)Potency29.08100.004110.890331.5287AID504467
USP1 protein, partialHomo sapiens (human)Potency0.35480.031637.5844354.8130AID743255
Microtubule-associated protein tauHomo sapiens (human)Potency14.12540.180013.557439.8107AID1460
67.9K proteinVaccinia virusPotency8.97160.00018.4406100.0000AID720579; AID720580
bromodomain adjacent to zinc finger domain 2BHomo sapiens (human)Potency70.79460.707936.904389.1251AID504333
lysosomal alpha-glucosidase preproproteinHomo sapiens (human)Potency22.38720.036619.637650.1187AID2100
nuclear factor erythroid 2-related factor 2 isoform 2Homo sapiens (human)Potency18.35640.00419.984825.9290AID504444
ras-related protein Rab-9AHomo sapiens (human)Potency5.01190.00022.621531.4954AID485297
DNA polymerase iota isoform a (long)Homo sapiens (human)Potency89.12510.050127.073689.1251AID588590
muscleblind-like protein 1 isoform 1Homo sapiens (human)Potency35.48130.00419.962528.1838AID2675
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
large T antigenBetapolyomavirus macacaeIC50 (µMol)11.99000.160024.9724100.0000AID1903
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
FAD-linked sulfhydryl oxidase ALRHomo sapiens (human)AC5016.98900.00503.212622.7870AID493248
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (18)

Assay IDTitleYearJournalArticle
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
AID592712Inhibition of GST-tagged Rad9/recombinant human N-terminal domain of RPA70 DNA binding domain interaction by electrophoretic mobility shift assay2011Bioorganic & medicinal chemistry, Apr-15, Volume: 19, Issue:8
Small molecule inhibitor of the RPA70 N-terminal protein interaction domain discovered using in silico and in vitro methods.
AID1853708Anti-biofilm activity against Pseudomonas aeruginosa PAO1 harboring wspF gene mutation assessed as reduction on c-di-GMP level by measuring GFP fluorescence at 100 uM incubated for 24 hrs by HPLC-MS/MS analysis2021RSC medicinal chemistry, Nov-17, Volume: 12, Issue:11
SAR study of 4-arylazo-3,5-diamino-1
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (10)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (10.00)29.6817
2010's7 (70.00)24.3611
2020's2 (20.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 24.49

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index24.49 (24.57)
Research Supply Index2.40 (2.92)
Research Growth Index4.52 (4.65)
Search Engine Demand Index17.79 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (24.49)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other10 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]